Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not responded to treatment. Previous research combined antibodies and T cells to treat cancer. Antibodies bind to foreign substances, and T cells are infection-fighting white blood cells that can kill tumor cells. Both approaches have shown promise but have not been sufficient to cure most patients. In prior studies, an antibody targeting CD30, a protein found on some T cells and cancer cells, was joined to T cells through gene transfer to create CD30.CAR T cells. Another study showed encouraging responses using CD30.CAR T cells made from a patient's own blood and returned to the same patient (autologous cells). In an ongoing study, patients have been treated with CD30.CAR T cells derived from healthy donors (allogeneic cells), allowing use of banked cells without individualized manufacturing. This approach has shown promising clinical activity with no safety concerns to date. In this study, investigators are evaluating CD30.CAR-EBVST cells modified with an additional molecule called C7R, which has been shown in laboratory studies to enhance anti-cancer effects. The study aims to assess the safety and effectiveness of these allogeneic, banked C7R-modified CD30.CAR-EBVST cells and determine whether they may help treat lymphoma. As an added safety measure, the modified T cells include a marker called iC9. If significant side effects occur, patients may receive rimiducid, which can eliminate the infused T cells. Rimiducid is not yet FDA approved but has been tested in patients without significant side effects.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie chłoniaka Hodgkina, chłoniaka B-komórkowego CD30-dodatniego, chłoniaka T-komórkowego lub zaawansowanego chłoniaka T-komórkowego
- •Potwierdzenie CD30-dodatniego guza w zatwierdzonym laboratorium
- •Wiek od 12 do 75 lat
- •Zanikające objawy poprzednich chemioterapii
- •Prawidłowe funkcje wątroby, nerek i oddychania
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
- •Chętni do stosowania antykoncepcji przez czas badania i 6 miesięcy po
- •Świadoma zgoda pacjenta lub opiekuna
✗ Disqualifies
- •Otrzymanie eksperymentalnego leczenia komórkowego w ostatnich 6 tygodniach
- •Otrzymanie poprzedniego leczenia anty-CD30 w ostatnich 4 tygodniach
- •Ciąża lub karmienie piersią
- •Wznowienie lub niekontrolowana infekcja (bakteryjna, wirusowa lub grzybiczna)
- •Poważne problemy z sercem uniemożliwiające uczestnictwo
- •Stosowanie wysokich dawek kortykosteroidów
- •Guz w miejscu, gdzie jego wzrost mogłby zablokować oddychanie
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Houston Methodist Hospital
Houston, United States
Texas Children's Hospital
Houston, United States
Trial contact
Premal Lulla, MD
Vicky Torrano, RN
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.